• Corpus ID: 73968628

Memantine: An oral NMDA antagonist for the treatment of moderate-to-severe Alzheimer's disease

  title={Memantine: An oral NMDA antagonist for the treatment of moderate-to-severe Alzheimer's disease},
  author={Brett Feret and Robert S. Dicks},
Memantine (Namenda, Forest) is the newest medication to receive FDA approval for the treatment of Alzheimer's disease and the first to be approved with a moderate-to-severe indication. All previously approved Alzheimer's disease treatments belong to the cholinesterase inhibitor class and are approved with a mild-to-moderate indication. Memantine has been used for more than 10 years in Germany and features a novel mechanism of action: N-methyl-D-aspartate (NMDA) antagonism. It has been shown to… 
Added Therapeutic Value of Memantine in the Treatment of Moderate to Severe Alzheimer’s Disease
In order to evaluate the benefit of monotherapy with the N-methyl-D-aspartate antagonist memantine in the management of moderate to severe Alzheimer’s disease, a systematic literature review was conducted and showed a benefit for Memantine in comparison with placebo in terms of a decrease in nursing care, adelay in care dependency and a delay in admission to nursing homes.
Why do many NMDA antagonists fail, while others are safe and effective at blocking excitotoxicity associated with dementia and acute injury?
The role of NMDA-mediated excitotoxicity in AD is explored, how the NMDAR functions is reviewed, the side effects and alternate signaling pathways that are initiated from N MDAR activation are highlighted, and why some NMDA antagonist compounds are effective and safe in limiting cascades of excitOToxicity in dementia or acute brain injury are discussed.
Memantine and progressive glaucoma.
A 75-year-old American woman with progressive open angle glaucoma underwent successful filtering surgery in both eyes in 1998 and at today’s visit has a new disc hemorrhage at the superior pole of her left disc.
Memantine destinee au traitement de la maladie d'alzheimer legere et legere a moderee
Cette invention concerne egalement un procede destine a empecher la baisse du metabolisme glucosique dans les zones corticales et sous-corticales du cerveau chez des sujets souffrant de the maladie d'Alzheimer legere, ou leger a moderee.
Shedding light on Alzheimer's.